Research and Publications
Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial
Van Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, Clack G, Barlow D, Makris A, Eastell R. J Clin Oncol. 2010 Feb 20;28(6):967-75. Epub 2010 Jan 11. PMID: 20065185 [PubMed - indexed for MEDLINE] http://www.ncbi.nlm.nih.gov/pubmed/20065185
Performance data of screening mammography at a dedicated breast health centre
Apffelstaedt JP, Steenkamp V, Baatjes K. S Afr Med J. 2008 Dec;98(12):950-3.PMID: 19374072 [PubMed - indexed for MEDLINE Performance data of screening mammography at a dedicated breast health centre
Counseling for male BRCA mutation carriers – a review
Mohamad HB, Apffelstaedt JP. Counseling for male BRCA mutation carriers - a review. Breast. 2008 Oct;17(5):441-50. Epub 2008 Jul 26. PMID: 18657973 [PubMed - in process]
Guideline implementation for breast healthcare in low- and middle-income countries : diagnosis resource allocation.
Shyyan R, Sener SF, Anderson BO, Fernández Garrote LM, Hortobágyi GN, Ibarra JA Jr, Ljung BM, Sancho-Garnier H, Stalsberg H; on behalf of the Breast Health Global Initiative Diagnosis Panel The Breast Health Global Initiative Diagnosis Panel members included Gaurav [...]
Conservative management of breast cancer in the elderly in a developing country
Wasserman LJ, Apffelstaedt JP, Odendaal Jde V. Conservative management of breast cancer in the elderly in a developing country. World J Surg Oncol. 2007 Oct 1;5:108. PMID: 17908323 [PubMed - indexed for MEDLINE]
Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial.
Tripathy D, Lichinitzer M, Lazarev A, MacLachlan SA, Apffelstaedt J, Budde M, Bergstrom B; MF 4434 Study Group. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. [...]